Meeder Asset Management Inc. Has $16.76 Million Position in Gilead Sciences, Inc. $GILD

Meeder Asset Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,945 shares of the biopharmaceutical company’s stock after selling 17,129 shares during the quarter. Gilead Sciences makes up 1.0% of Meeder Asset Management Inc.’s holdings, making the stock its 26th biggest position. Meeder Asset Management Inc.’s holdings in Gilead Sciences were worth $16,755,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. GoalVest Advisory LLC lifted its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the second quarter worth approximately $27,000. Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $30,000. Finally, Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.4%

Shares of GILD opened at $121.10 on Monday. The firm has a 50 day simple moving average of $123.27 and a two-hundred day simple moving average of $117.67. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70. The company has a market cap of $150.25 billion, a P/E ratio of 18.78, a P/E/G ratio of 0.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the company posted $2.02 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 48.99%.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. TD Cowen lifted their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Argus upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Finally, HSBC boosted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $133.20.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the sale, the chief executive officer owned 566,698 shares in the company, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the sale, the insider directly owned 106,221 shares in the company, valued at approximately $12,958,962. The trade was a 2.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 136,257 shares of company stock worth $16,855,192 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.